Mergers: Commission approves the merger of Mylan and Pfizer’s Upjohn division, subject to conditions

This article is brought to you in association with the European Commission. The European Commission has approved, under the EU Merger Regulation, the proposed merger between the global pharmaceutical company Mylan and Upjohn, a business division of Pfizer, which operates Pfizer’s off-patent branded and generic established medicines. The decision is conditional on the divestment of Mylan’s […]

Mergers: Commission approves GlaxoSmithKline’s acquisition of Pfizer’s Consumer Health Business, subject to conditions

This article is brought to you in association with the European Commission. The European Commission has approved, under the EU Merger Regulation, the acquisition of Pfizer’s Consumer Health Business by GlaxoSmithKline. The decision is conditional upon the global divestment of Pfizer’s topical pain management business carried out under the ThermaCare brand. GlaxoSmithKline (“GSK”) and Pfizer’s Consumer Health Business […]

Is there a drug for every disease?

Pharmaceutical firms in Europe have an awkward relation with their customers. The truth is that their selling prices and product licencing are directly or indirectly controlled by the buyers, that is governments, or government control health insurance schemes, offering almost free health services to citizens. As everybody knows governments are not only able to influence […]